New hope for Hard-to-Treat prostate cancer: drug combo trial launches
Disease control
Not yet recruiting
This phase 2 trial tests whether adding mevrometostat to enzalutamide can slow cancer growth in 60 men with metastatic castration-resistant prostate cancer who have already been treated with similar drugs. Participants will take both drugs orally. The main goal is to see how long…
Phase: PHASE2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC